Gyroscope Therapeutics Announces Appointment of Tony Adamis to Board of Directors LONDON – 6 December 2021 –Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company focused on diseases of the eye, today announced the appointment of biotech industry...
Gyroscope Therapeutics Announces Sanofi Investment of up to $60 Million Investment Further Validates Potential of Investigational Gene Therapy GT005 in Geographic Atrophy and Supports Ongoing Phase II Development Programme LONDON – 8 November 2021 – Gyroscope...
Gyroscope Therapeutics Announces Presentation of Positive Interim Phase I/II Data for Investigational Gene Therapy GT005 at Retina Society Annual Scientific Meeting GT005 Continues to be Well Tolerated with Encouraging Biomarker Results in Patients with Geographic...
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.